Double-Duty mRNA vaccine targets RSV and hMPV in early trial
NCT ID NCT06237296
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested an experimental mRNA vaccine designed to protect against two respiratory viruses: RSV and hMPV. Healthy adults aged 18 to 49 and 60 years and older received a single injection of the vaccine at different doses. The main goals were to check safety and measure the immune response, not yet to prove it prevents illness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mRNA vaccine targeting RSV and hMPV viruses
- What this could lead to
- If successful, this could lead to a single vaccine that protects against two common respiratory viruses, reducing severe lung infections in older adults.
- What could go wrong
- This is an early Phase 1 trial focused on safety and immune response, not yet on preventing disease. The vaccine may not produce strong enough immunity or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Advanced Clinical Research- Site Number : 8400005
Meridian, Idaho, 83642, United States
-
Charlottesville Medical Research Center Winding River - Site Number : 8400002
Charlottesville, Virginia, 22911, United States
-
Coastal Carolina Research Center- Site Number : 8400001
North Charleston, South Carolina, 29405, United States
-
Investigational Site Number : 0360001
Camberwell, Victoria, 3124, Australia
-
Investigational Site Number : 0360002
Botany, New South Wales, 2019, Australia
-
Investigational Site Number : 0360003
Kanwal, New South Wales, 2259, Australia
-
Investigational Site Number : 0360004
Sydney, New South Wales, 2035, Australia
-
Investigational Site Number : 0360005
Morayfield, Queensland, 4506, Australia
-
Investigational Site Number : 0360006
Blacktown, New South Wales, 2148, Australia
-
Investigational Site Number : 0360007
Canberra, 2617, Australia
-
Investigational Site Number : 0360008
Herston, Queensland, 4006, Australia
-
Meridian Clinical Research- Site Number : 8400007
Binghamton, New York, 13905, United States
-
Velocity Clinical Research, Sioux City Site Number : 8400017
Sioux City, Iowa, 51106, United States
-
Velocity Clinical Research- New Orleans Site Number : 8400016
New Orleans, Louisiana, 70119, United States
-
Velocity Clinical Research- Site Number : 8400012
Cleveland, Ohio, 44122, United States
-
Velocity Clinical Research-Hallandale Beach- Site Number : 8400013
Hallandale, Florida, 33009, United States
-
Velocity Gardena Site Number : 8400011
Gardena, California, 90247, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults